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Effective behaviour change techniques in smoking
cessation interventions for people with chronic
obstructive pulmonary disease: A meta-analysis
Yvonne K. Bartlett1, Paschal Sheeran2 and Mark S. Hawley1*
1School of Health and Related Research, University of Sheffield, UK
2Department of Psychology, University of Sheffield, UK
Purpose. The purpose of this study was to identify the behaviour change techniques
(BCTs) that are associated with greater effectiveness in smoking cessation interventions
for people with chronic obstructive pulmonary disease (COPD).
Methods. A systematic review and meta-analysis was conducted. Web of Knowledge,
CINAHL, EMBASE, PsycINFO, andMEDLINEwere searched from the earliest date available
to December 2012. Data were extracted and weighted average effect sizes calculated; BCTs
used were coded according to an existing smoking cessation-specific BCT taxonomy.
Results. Seventeen randomized controlled trials (RCTs) were identified that involved a
total sample of 7446 people with COPD. The sample-weighted mean quit rate for all
RCTs was 13.19%, and the overall sample-weighted effect size was d+ = 0.33.
Thirty-seven BCTs were each used in at least three interventions. Four techniques were
associated with significantly larger effect sizes: Facilitate action planning/develop treatment
plan, Prompt self-recording, Advise on methods of weight control, and Advise on/facilitate use of
social support. Three new COPD-specific BCTs were identified, and Linking COPD and
smoking was found to result in significantly larger effect sizes.
Conclusions. Smoking cessation interventions aimed at people with COPD appear to
benefit from using techniques focussed on forming detailed plans and self-monitoring.
Additional RCTs that use standardized reporting of intervention components and BCTs
would be valuable to corroborate findings from the present meta-analysis.
Statement of contribution
What is already known on this subject? Chronic obstructive pulmonary disease (COPD) is
responsible for considerable health and economic burden worldwide, and smoking cessation (SC) is
the only known treatment that can slow the decline in lung function experienced. Previous reviews of
smoking cessation interventions for this population have established that a combination of
pharmacological support and behavioural counselling is most effective. While pharmacological
support has been detailed, and effectiveness ranked, the content of behavioural counselling varies
between interventions, and it is not clear what the most effective components are.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
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What does this study add?
 Detailed description of ‘behavioural counselling’ component of SC interventions for people with
COPD.
 Meta-analysis to identify effective behaviour change techniques tailored for this population.
 Discussion of these findings in the context of designing tailored SC interventions.
Chronic obstructive pulmonary disease (COPD) is a term used to describe progressive,
non-reversible airflow obstruction (Department of Health [DoH], 2005). Approximately
80% of cases are linked to smoking (DoH, 2005) with the other 20% due to a combination
of environmental and genetic factors (National Institute for Health and Clinical
Excellence [NICE], 2010). In 2004, COPD was estimated to cost the National Health
Service (NHS) £800 million in direct care costs and was responsible for 24 million lost
work days (DoH, 2005). The prevalence and costs associated with COPD are expected to
rise in the coming years (Parker & Eaton, 2012), and by 2020, it is estimated that COPD
will be the third leading cause of death worldwide (World Health Organisation [WHO],
2002).
There is no cure for COPD (DoH, 2005). To date, the only intervention found to slow
the decline in lung functioning is smoking cessation (Anthonisen et al., 1994). Current
best practice advises that people with COPD be encouraged to quit smoking and given all
necessary psycho-social and/or pharmacological support to do so (NICE, 2010).
Nevertheless, the proportion of people with COPD continuing to smoke has been
estimated between 32.8% and 70% (Baron, 2003; Vozoris & Stanbrook, 2011) and could be
rising (Vozoris & Stanbrook, 2011). The current advice to physicians in the United
Kingdom and the United States is that people with COPD should be given advice at every
opportunity and, if the person is agreeable, should be referred to a local smoking cessation
service (NICE, 2010; Parker & Eaton, 2012). In the United Kingdom, this is the NHS Stop
Smoking Services (SSS). Target quit rates for theNHS SSS are between 35% and 70% (Willis,
2008). However, the SSS are not specifically designed for people with COPD. Evidence
suggests that smokers with COPD have greater dependence on nicotine than those with
normal lung functioning (Jimenez-Ruiz et al., 2001) and find it harder to quit (Tashkin &
Murray, 2009). Continued smoking by people with COPD increases hospital admissions
and negatively affects morbidity and mortality (Global Initiative for Chronic Obstructive
Lung Disease [GOLD], 2011). In a recent simulation, it was estimated that continued
smoking by people with COPD in England alone would result in costs of £1,657 million
over a 10-year time period and that smoking cessation was cost–effective regardless of
disease stage (Atsou, Chouaid, & Hejblum, 2011). Despite the health and economic
benefits of encouraging smoking cessation in this population, there is relatively little
evidence of smoking cessation interventions that are tailored for this group (Parker &
Eaton, 2012).
Rationale for the present review: Identifying effective behaviour change techniques
Previous systematic reviews addressing smoking cessation in people with COPD have
concluded that a combination of stop smoking medication (SSM) and non-pharmacolog-
ical approaches offers the most effective smoking cessation intervention for people
with COPD. This finding has been supported by meta-analyses (van der Meer, Wagena,
Ostelo, Jacobs, & van Schayck, 2003; Strassmann et al., 2009), economic modelling
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(Hoogendoorn, Feenstra, Hoogenveen, &Rutten-vanMolken, 2010), and narrative review
(Parker & Eaton, 2012; Warnier, Riet, Rutten, Bruin, & Sachs, 2012). However, although
the SSMcomponents have been ranked in terms of effectiveness (Strassmann et al., 2009),
the efficacy of the non-pharmacological components (typically referred to as ‘behavioural
counselling’) has not previously been assessed. What constitutes ‘behavioural counsel-
ling’ varies considerably between interventions (Michie & Abraham, 2008). Parker and
Eaton (2012) suggest that counselling ‘should assist in motivating the smoker to quit
smoking and developing skills and strategies to cope with nicotine withdrawal, and …
should also help the smoker identify cues and situations that would lead to temptation or
pressure to smoke’ (p. 161), although they did not describe which of the existing
interventions contain these elements, or their potential relationship with intervention
outcomes.
Abraham and Michie (2008) developed a taxonomy of the ‘active ingredients’ or
behaviour change techniques (BCTs) used in behavioural interventions to improve
comparisons between studies and enable conclusions about the efficacy of specific
intervention components (Abraham & Michie, 2008). Michie and colleagues produced a
taxonomy of the BCTs used in smoking cessation studies (Michie, Churchill, & West,
2011; Michie, Hyder, Walia, & West, 2011). Michie, Hyder, et al.’s (2011) taxonomy
contains 53 specific BCTs categorized into groups according the function they perform
(Table S1). Techniques coded with a ‘B’ have a specific focus on behaviour and are split
into ‘BM’ (which address motivation) and ‘BS’ (which focus on self-regulatory capacity
and skills). Techniques coded with an ‘A’ promote adjuvant activities and an ‘R’ focus on
more general aspects of the interaction; ‘RD’ describes aspects of delivery, ‘RI’ codes for
aspects of information gathering and ‘RC’ for general communication (Michie, Hyder,
et al., 2011). These groups outline the target areas for smoking cessation counselling.
However, within these codes, the taxonomy defines specific BCTs used to achieve these
targets (see Table S1 for examples). This taxonomy has been used to classify existing
interventions and services for the general population of smokers (West, Walia, Hyder,
Shahab, & Michie, 2010), the content of a text message-based intervention for smoking
cessation (Michie, Free, & West, 2012), and smoking cessation interventions during
pregnancy (Lorencatto, West, & Michie, 2012). This method has not heretofore been
applied to smoking interventions among people with COPD.
The purpose of this review is to identifywhich BCTs are associatedwithmore effective
smoking cessation interventions for peoplewith COPD.Discovering effective BCTs could
guide the development of future interventions tailored to theCOPDpopulation, to ensure
maximum impact on cessation rates.
Methods
Search strategy
The present review was part of a larger review of behaviour change interventions in
people with COPD in which smoking, exercise, and breathing training behaviours were
investigated. Briefly, the search strategy comprised of COPD terms AND intervention/
behaviour terms AND smoking terms OR exercise terms OR breathing training terms (for
the full strategy, see Appendix 1). The full search strategy (optimized for each database)
was run in CINAHL, MEDLINE, PsycINFO, Web of Knowledge (all databases), and
EMBASE. Articles that cited, or were cited by, included studies, and applicable reviews
were assessed. A reduced search (COPDANDbehav$) was conducted in PASCAL, ESTAR,
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AMED, and the Applied Social Sciences Index and Abstracts. The search was last updated
on 27 December 2012.
Inclusion and exclusion criteria
Papers were included if (1) smokers with a diagnosis of COPD were participants, (2) a
randomized controlled trial (RCT) of an intervention that aimed to alter participants’
behaviour was reported, and (3) a measure of smoking cessation was reported.
Unpublished papers and papers not written in English were excluded.
Outcome definitions
The outcome of interest was smoking cessation (quit rate), measured by either point
prevalence (PP) or continuous abstinence (CA)measures. PPmeasures smoking status at a
specific point in time, or for a period immediately before this point; typically these
measures assess whether or not the person has smoked in the last 7 days. CA measures
sustained abstinence over a longer period of time, with smoking status measured on two
or more occasions. Both CA and PP can be assessed using self-report, biochemical
validation, or both.
Quality assessment
Study quality was assessed using the Delphi list (Verhagen et al., 1998). A score of
five or greater indicates a ‘high-quality study’ according to a related Cochrane review
(van der Meer et al., 2003). Power and attrition rates were also calculated for each
study.
Coding of interventions
Interventions were coded according to a 53-item taxonomy that is specific to smoking
cessation (Michie, Churchill, et al., 2011). To ensure comprehensive coding of the
interventions, authors were contacted for any additional materials such as protocols or
training materials. All English language resources provided were coded in addition to the
publication. Intervention descriptions were coded by a researcher familiar with the
taxonomy who had undergone training in the use of BCT taxonomies. Fifteen of the 17
interventions were further independently coded by an expert in using this taxonomy.
Initial agreement between the two coders was 89.31%with a kappa coefficient of .7. This
represents ‘substantial agreement’ (Landis & Koch, 1977). Disagreements were resolved
by discussion.
The BCT taxonomy contains several codes related to SSM, namely Advise on stop
smoking medication, Adopt appropriate local procedures to enable clients to obtain
free medication, and Ask about experiences of stop smoking medication that the
smoker is using. However, these codes do not differentiate between SSM being a
prescribed, integral part of the intervention, and advice and free SSM being provided (or
suggested) for use at the participant’s discretion. Studies that used SSM as a mandatory
part of the intervention protocol (including prescribed doses) were additionally coded as
‘SSM’ studies. A further three COPD-specific BCTs were identified, namely COPD
medication advice, where advice was given regarding non-study medication that is not
SSM (e.g., advice on, or optimization of COPD-related medication), COPD-specific
184 Yvonne K. Bartlett et al.
information, where advice about areas of COPD management in addition to smoking
cessation is given (e.g., breathing training), and Linking COPD and smoking, where an
explicit link is drawnbetween the participant’s smoking and their COPD (e.g., referring to
the participant as having ‘smoker’s lung’).
Assessment of effectiveness and meta-analytic strategy
The effectiveness of smoking cessation interventions was assessed by two indices, the
sample-weighted quit rates and d+. Both indices were computed using the PP and CA
rates. If PP and CA rates were both reported, the outcome with the highest ranking
according to Eisenberg et al. (2008) was used to calculate the most conservative estimate
for each study. Eisenberg et al. ranked biochemically validated CA at 12 months most
highly, followed by CA at 6 months, PP at 12 months, and finally PP at 6 months. Effect
sizes were calculated using META 5.3 (Schwarzer, 1987). Random effects models were
used as effect sizes from the individual studies were expected to be heterogeneous.
STATA version 11 (Statacorp., 2009) was used to generate the funnel plot and to estimate
small-sample bias via Egger’s regression.
Potential moderators of effectiveness considered were BCTs used, study quality,
study design, intervention features, type of outcome measure, and the use of SSM. For
dichotomous moderators (e.g., presence vs. absence of a specific BCT), the average
effect size was computed when there were at least three independent tests for both
levels of the moderator, and the between-groups heterogeneity statistic (Qb) was used
to compare the effect sizes (Webb & Sheeran, 2006). SPSS 18 (SPSS Inc., 2009) was
used to compute associations between continuous moderator variables and effect sizes
using weighted least squares (WLS) regression (i.e., effect sizes were weighted by the
respective sample n).
Results
Studies included in the review
The flow of articles through the review is shown in Figure 1. A total of 17 eligible
interventions were identified with a total sample of 7,446 people with COPD (see
Table S2, included studies are indicated in the reference list). Mean age ranged from 48 to
67 years; 42.72% of the overall sample was female (Table S3). In studies reporting FEV1 %
pred,1 values ranged from 52% to 80% (k = 8), which is considered moderate severity
according to the GOLD (2011) standards.
The interventions mainly compared intervention conditions with usual care (k = 12).
Four studies were placebo-controlled drug trials, and one study compared two active
conditions (Table S2). Intervention duration ranged from 22 days to 5 years
(Mdn = 85 days; k = 12). The longest follow-up (after all active components of the
intervention had stopped) ranged from immediately to 2 years (k = 13). The main
delivery modes (k = 17) were one-to-one (70.59%) or a mixture of both one-to-one and
group delivery (29.41%). Intervention setting (k = 17) varied between studies; 64.71%
had at least some of the components delivered in the participant’s home, and 35.29%were
delivered exclusively in a clinical setting (Table S2).
1 Forced expiratory volume in one-second, presented as a% of what would be expected for someone of the same age, gender, and
height.
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Quality assessment
Overall, 58.82% of studies (k = 10) reached the ≥5 threshold for ‘high quality’ (van
der Meer et al., 2003). The average quality rating overall was 5.47 (SD = 2.29;
Table 1). Ten studies reported an a priori power calculation to identify a desired
sample size, although only five of these studies reached their target sample size.
Post-hoc power could be calculated for 15 studies; power ranged from 8% to 100%
with an average of 63.47% (SD = 0.30). Ten studies reached the threshold for
adequate power (55%) suggested by Coyne, Thombs, and Hagedoorn (2010). Attrition
rate was the percentage of randomized participants who began the intervention, but
did not complete the longest follow-up (M = 17.46%, SD = 10.53), where reported
mean dropout during the intervention period was 16.69% (SD = 15.69). Overall,
the quality of studies included in the review could be considered satisfactory
(Table 1).
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Effectiveness of smoking cessation interventions
Individual study quit rates ranged from0% (Wilson, Fitzsimons, Bradbury, & Elborn, 2008)
to 28.9% (Brandt et al., 1997). The overall sample-weighted average quit rate was 13.19%.
The d+ was 0.33 (Table 2). One study had a very large sample size and longer follow-up
period comparedwith the other studies (Anthonisen et al., 1994). However, deleting this
study did not significantly change the average effect size (d+ = 0.31) or improve
homogeneity. The effect size for the nine studieswith adequate powerwas 0.37; this value
did not differ significantly from studies with inadequate power (d+ = 0.22). The funnel
plot appeared symmetrical (Figure S1), and Egger’s regression revealed no significant bias
in the observed effect sizes (B = 1.06, SE = 0.58, ns). These findings suggest that
publication bias does not present a problem for the present meta-analysis.
Potential moderators of the observed effect sizes were tested using the Qb statistic
(Table 2). The effect size for measures of CA (k = 11, d+ = 0.42) was higher than those
studies reporting only PP (k = 6, d+ = 0.29), but the difference did not reach significance
(Qb = 3.58, p = .06). The nature of the comparison group (usual care vs. placebo) did not
influence effect sizes (Table 2). However, the provision of SSMs and both delivery and
setting of the interventions were significant moderators. Interventions that provided SSM
as a mandatory part of their protocol (k = 7, d+ = 0.42) were more effective than
interventions that did not (k = 10, d+ = 0.32), Qb = 26.24, p < .001. Interventions
delivered exclusively in a clinical setting (k = 6, d+ = 0.37) had a significantly higher d+
than those that contained either home components, or were delivered exclusively at
home (k = 11, d+ = 0.28), Qb = 13.34, p < .001. Interventions containing group
components (k = 4, d+ = 0.49) had a significantly higher effect size than one-to-one-only
interventions (k = 12, d+ = 0.26), Qb = 49.77, p < .001. Potential continuous modera-
tors were entered intoWLS regressions. Study quality (k = 17, b = .27, p = .30), duration
of the intervention (k = 13, b = .48, p = .10), the time between the end of the
intervention to the longest follow-up (k = 13,b = .07,p = .82), and attrition rate (k = 17,
b = .245, p = .34) did not significantly predict effect sizes.
BCTs and intervention effectiveness
Of the 53 smoking cessation BCTs identified by Michie, Churchill, et al. (2011), 47 were
used in one or more of the interventions. The number of techniques used in each
intervention ranged from 1 to 28, with an average of 13.11 (SD = 8.63; Table S2). The
most frequently used individual techniquewasBoostmotivation and self-efficacy, which
was used in 70.59% of the interventions.
The impact of presence versus absence of particular BCTs on effectiveness was tested
using theQb statistic (Table 2). Two techniqueswere associatedwith reducedeffectiveness
(Boostmotivationand self-efficacy andAssessnicotinedependence).However, therewere
positive effects for four techniques: Interventions that deployed Facilitate action
planning/develop treatment plan, Prompt self-recording, Advise on methods of weight
control, andAdvise on/facilitate use of social support each engendered significantly larger
effect sizes compared with studies that did not use these techniques.
Two groups of BCTs had ≥3 studies in both presence and absence levels to be analysed.
Interventions that used BCTs focussing on self-regulatory capacity/skills (BS codes) and
interventions that promoted adjuvant activities (A codes) were compared with interven-
tions that did not; neither comparison was significant (Qb = 1.13, p = .29 andQb = 0.89,
p = .34 respectively). The provision of COPD-specific information or COPDmedication
advice was not associated with effect sizes (Qb = 1.35, p = .25 and Qb = 0.02, p = .88,
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Table 2. Overall effect sizes, homogeneity, and moderator analyses
Measure k n d+
95% Confidence
intervals
Homogeneity
analysis
Lower Upper Qw Qb
Overall 17 7,446 0.33 0.23 0.43 41.55***
Outliers 0.23
Excluding Anthonisen et al. (1994) 16 3,521 0.31 0.20 0.42 29.92*
Quality 3.10
Adequate power and sample sizea 9 6,833 0.37 0.27 0.48 26.7***
Inadequate power and sample sizea 8 613 0.22 0.00 0.43 7.28
Intervention designb 0.26
Drug versus placebo 4 1,417 0.31 0.21 0.42 2.61
Intervention versus usual care 12 5,996 0.34 0.20 0.48 33.84***
Setting 13.34***
Home component 11 2,666 0.28 0.19 0.37 24.01**
Exclusively medical setting 6 4,780 0.46 0.37 0.55 2.94
Deliveryc 49.77***
Group components 4 4,749 0.49 0.34 0.64 6.07
One-to-one only 12 2,606 0.26 0.14 0.38 11.86
Medication 26.23***
SSM 7 5,736 0.42 0.37 0.48 12.83*
No SSM 10 1,710 0.32 0.13 0.50 26.48**
Outcome 3.58
PP 6 1,133 0.29 0.00 0.57 9.11
CA 11 6,313 0.42 0.36 0.48 24.02**
BM1 ‘Provide information on the health
consequences of smoking and
smoking cessation’
1.87
Present 8 6,350 0.36 0.21 0.50 27.01***
Absent 9 1,096 0.27 0.11 0.44 7.29
BM2 ‘Boost motivation and self-efficacy’ 7.29**
Present 12 2,940 0.30 0.21 0.39 26.43**
Absent 5 4,506 0.43 0.21 0.65 5.54
BM3 ‘Provide feedback on current
behaviour and progress’
1.06
Present 5 4,668 0.35 0.11 0.59 16.26**
Absent 12 2,778 0.30 0.19 0.41 11.91
BM4 ‘Provide rewards contingent on
successfully stopping smoking’
0.66
Present 3 853 0.38 0.24 0.52 0.37
Absent 14 6,593 0.32 0.19 0.44 41.03***
BM6 ‘Prompt commitment from the
client there and then’
0.14
Present 3 742 0.36 0.22 0.51 1.49
Absent 14 6,704 0.33 0.21 0.45 39.69***
BM7 ‘Provide rewards contingent on
effort or progress’
2.03
Present 3 634 0.42 0.05 0.79 7.45*
Absent 14 6,812 0.30 0.20 0.41 31.59**
Continued
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Table 2. (Continued)
Measure k n d+
95% Confidence
intervals
Homogeneity
analysis
Lower Upper Qw Qb
BM9 ‘Conduct motivational interviewing’ 0.04
Present 4 412 0.34 0.06 0.74 5.59
Absent 13 7,034 0.36 0.29 0.44 33.89***
BM10 ‘Identify reasons for wanting
and not wanting to stop smoking’
2.78
Present 4 543 0.21 0.04 0.39 1.52
Absent 13 6,903 0.36 0.23 0.48 34.89***
BS1 ‘Facilitate barrier identification
and problem-solving’
3.00
Present 7 2,177 0.28 0.11 0.46 23.45***
Absent 10 5,269 0.37 0.26 0.48 13.92
BS2 ‘Facilitate relapse prevention
and coping’
0.17
Present 11 6,556 0.33 0.23 0.43 34.4***
Absent 6 890 0.36 0.14 0.59 6.72
BS3 ‘Facilitate action planning/develop
treatment plan’
4.72*
Present 7 5,057 0.44 0.39 0.50 11.71
Absent 10 2,389 0.33 0.17 0.50 24.19**
BS4 ‘Facilitate goal setting’ 0.17
Present 10 6,552 0.31 0.18 0.44 36.79***
Absent 7 894 0.34 0.20 0.49 3.59
BS5 ‘Prompt review of goals’ 1.08
Present 4 1,028 0.28 0.14 0.43 4.25
Absent 13 6,418 0.35 0.23 0.48 34.17***
BS6 ‘Prompt self-recording’ 4.83*
Present 5 4,962 0.40 0.22 0.57 16.10**
Absent 12 2,484 0.29 0.15 0.42 13.86
BS8 ‘Advise on environmental
restructuring’
0.14
Present 3 742 0.36 0.22 0.51 1.49
Absent 14 6,704 0.33 0.21 0.45 39.69***
BS13 ‘Advise on methods of weight
control’
33.48***
Present 3 4,539 0.53 0.37 0.69 4.35
Absent 14 2,907 0.25 0.15 0.36 13.42
A1 ‘Advise on stop smoking medication’ 0.67
Present 10 6,593 0.35 0.23 0.47 29.27***
Absent 7 853 0.29 0.09 0.49 6.61
A2 ‘Advise on/facilitate use of social
support’
8.00**
Present 7 5,372 0.40 0.23 0.57 13.40*
Absent 10 2,074 0.25 0.11 0.39 7.99
Continued
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Table 2. (Continued)
Measure k n d+
95% Confidence
intervals
Homogeneity
analysis
Lower Upper Qw Qb
A3 ‘Adopt appropriate local procedures
to enable clients to obtain free
medication’
0.15
Present 7 5,256 0.37 0.28 0.45 15.73*
Absent 10 2,190 0.35 0.20 0.51 24.21**
A4 ‘Ask about experiences of stop
smoking medication that the
smoker is using’
3.45
Present 3 4,608 0.40 0.25 0.56 3.82
Absent 14 2,838 0.31 0.18 0.43 28.12**
A5 ‘Give options for additional and
later support’
0
Present 8 5,787 0.36 0.28 0.44 21.82**
Absent 9 1,659 0.36 0.19 0.54 18.98*
RD1 ‘Tailor interactions appropriately’ 3.43
Present 10 6,498 0.37 0.20 0.54 31.53***
Absent 7 948 0.24 0.11 0.37 3.23
RD2 ‘Emphasize choice’ 3.48
Present 6 5,445 0.41 0.33 0.48 10.99
Absent 11 2,001 0.31 0.14 0.47 26.23**
RI1 ‘Assess current and past smoking
behaviour’
0.03
Present 11 6,114 0.36 0.27 0.45 29.39**
Absent 6 1,332 0.35 0.12 0.57 7.27
RI2 ‘Assess current readiness and
ability to quit’
0.04
Present 8 5,300 0.35 0.25 0.45 16.25*
Absent 9 2,146 0.36 0.21 0.51 21.94**
RI3 ‘Assess past history of quit attempts’ 1.39
Present 3 774 0.26 0.05 0.48 3.90
Absent 14 6,672 0.35 0.23 0.46 35.83***
RI5 ‘Assess nicotine dependence’ 9.12**
Present 5 1,242 0.19 0.07 0.31 4.17
Absent 12 6,204 0.39 0.27 0.51 23.67*
RI7 ‘Assess attitudes to smoking’ 2.50
Present 3 485 0.21 0.03 0.39 1.47
Absent 14 6,961 0.36 0.24 0.47 35.22***
RI10 ‘Assess physiological and mental
functioning’
0.71
Present 4 4,274 0.37 0.04 0.78 11.50**
Absent 13 3,172 0.33 0.26 0.40 23.24*
RC1 ‘Build general rapport’ 0.17
Present 4 4,410 0.32 0.14 0.50 9.15*
Absent 13 3,036 0.34 0.21 0.46 26.83**
Continued
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respectively). However, interventions that involved Linking COPD and smoking
generated larger effect sizes (Qb = 8.42, p < .01).
Discussion
Seventeen RCTs of smoking cessation interventions for people with COPD were
identified. The sample-weighted average quit rate across these trials was 13.19%. This
rate is higher than the 5% expected quit rate for general population smokers with no
Table 2. (Continued)
Measure k n d+
95% Confidence
intervals
Homogeneity
analysis
Lower Upper Qw Qb
RC4 ‘Explain expectations regarding
treatment programme’
2.07
Present 4 4,641 0.39 0.26 0.53 5.55
Absent 13 2,805 0.32 0.19 0.44 27.34**
RC5 ‘Offer/direct towards appropriate
written materials’
0.28
Present 9 5,872 0.41 0.36 0.46 21.77***
Absent 8 1,574 0.38 0.19 0.58 19.58**
RC6 ‘Provide information on withdrawal
symptoms’
2.41
Present 6 1,535 0.39 0.24 0.54 12.75*
Absent 11 5,911 0.30 0.16 0.44 28.78**
RC8 ‘Elicit client views’ 0.36
Present 5 1,042 0.31 0.19 0.43 3.93
Absent 12 6,404 0.35 0.22 0.49 34.87***
COPD medication advice 0.02
Present 4 247 0.37 0.03 0.76 5.82
Absent 13 7,199 0.35 0.26 0.43 34.44***
COPD-specific information 1.35
Present 7 1,489 0.35 0.11 0.59 23.61***
Absent 10 5,957 0.42 0.37 0.47 16.15
Link between COPD and smoking 8.42**
Present 4 4,524 0.45 0.39 0.51 6.11
Absent 13 2,922 0.31 0.18 0.45 28.92**
BS ‘Specific focus on behaviour,
maximizing self-regulatory capacity/skills’
1.13
Present 13 7,190 0.32 0.23 0.42 38.92***
Absent 4 256 0.46 0.18 0.75 2.50
A ‘Promote adjuvant activities’ 0.89
Present 13 7,169 0.33 0.24 0.42 38.72***
Absent 4 277 0.45 0.14 0.76 2.79
Note. SSM = stop smoking medication.
aDefined as power >0.5 and sample size ≥35 in each cell (Coyne et al., 2010); bOne study compared two
active conditions; ck = 15Wilson et al., excluded as their experimental groups compared individual and
group support.
*Significant at p < .05; **significant at p < .01; ***significant at p < .001.
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help (Hughes, Keely, & Naud, 2004), marginally higher than the 12.3% quit rate reported
in a previous review of people with COPD (Hoogendoorn et al., 2010), and lies within
the range of general population quit rates in response to behavioural interventions for
smoking (Poulsen, Dollerup, & Moller, 2010). It has been reported that people with
COPD find it harder to quit than the general population of smokers (Tashkin & Murray,
2009), so it was expected that the quit rate observed here (13%) falls below the
minimum expected quit rate of 35% in the SSS (Willis, 2008) and below the actual quit
rate of 49% achieved by NHS SSS across England in 2011/2012 (The Health and Social
Care Information Centre, 2012). It is notable that no statistics are available for quit rates
for people with COPD through the SSS. However, the relatively high prevalence of
COPD suggests that even a quit rate of 13% would be important for health care services
(Tashkin & Murray, 2009). The magnitude of the sample-weighted average effect size is
also consistent with the idea that smoking cessation interventions for people with COPD
were generally effective. The effect size observed here (d+ = 0.33) is in the modal range
obtained in a review of 302 meta-analyses of psychological and behavioural treatments
(Lipsey & Wilson, 1993).
Interventions containing group elements and those delivered within a clinical setting
were found to be effective in this population. The increased benefit of including group
elements, over and above individual counselling, in smoking cessation interventions for
the general population is currently unclear (Stead & Lancaster, 2009). Further research is
needed to ascertain whether this approach is more effective for people with COPD than
the general population of smokers. Smoking cessation interventions delivered while
patients are hospitalized, with a range of conditions, and containing follow-up extending
beyond the period of hospitalization have been found to bemore effective than usual care
in ameta-analysis (Munafo, Rigotti, Lancaster, Stead,&Murphy, 2001).Clinical settings are
smoke-free environments, and all other cues to smoking associated with being in the
home would be removed in these interventions; these additional factors may have
contributed to interventions delivered in a clinical setting beingmore effective for people
with COPD.
A novel feature of the present meta-analysis was that the BCTs used in smoking
cessation interventions for people with COPD were coded, and their impact on
effectiveness was tested. Across all 17 interventions, four established BCTs were
associated with significantly larger effect sizes: Facilitate action planning/develop
treatment plan,Prompt self-recording,Advise onmethods ofweight control, andAdvise
on/facilitate use of social support. In addition, one new COPD-specific BCT Linking
COPD and smoking was also found to be associated with larger effect sizes. Forming
detailed plans of what, when, and how to achieve a behaviour change have been found to
be effective in achieving a wide range of behaviour change targets (Gollwitzer & Sheeran,
2006). Implementation intentions take the format of if–then plans and have been found to
be effective not only in promoting initial changes in behaviour (Sheeran & Orbell, 1999),
but also in protecting ongoing behavioural performance from antagonistic feelings and
cognitions (Achtziger, Gollwitzer, & Sheeran, 2008; Martin, Slade, Sheeran, Wright, &
Dibble 2011). The current findings suggest that: prompting the formation of if–then plans,
providing information about how to handle weight gain as a possible side effect of
cessation, and facilitating self-monitoring of current behaviour and progress towards the
goal could each constitute useful components of smoking cessation interventions for this
population.
The finding that Advise on/facilitate use of social supportwas associated with more
effective smoking cessation interventions for people with COPD echoes the results of a
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previous review concerning smoking cessation in the general population (West et al.,
2010). However, eight techniques that West et al. found were effective in the general
population (and were used in ≥3 tests in the present review) were not associated with
effect sizes here. These findings suggest that although fewer techniques are effective for
people with COPD than for members of the general public, social support is an
important aid to quitting for all smokers. Such findings also imply that it may be
advantageous to tailor smoking cessation efforts to the target sample as it cannot be
assumed that BCTs that are effective for members of the general public are similarly
effective for specific groups.
Two techniques, Assess nicotine dependence and Boost motivation and self-efficacy,
were contraindicated among smokers with COPD. One possible explanation for the
negative effect of assessing nicotine dependence is that such assessment could reinforce
the idea that the person is ‘addicted’ to smoking and thus reduce self-efficacy in relation to
quitting. Further primary research on how best to feed back nicotine dependence
assessments is needed to test this hypothesis. A possible explanation for the second
contraindicated BCT is that smokers with COPD who take part in smoking cessation
interventions may already be highly motivated to quit. Additional attempts to boost
motivation and self-efficacy could therefore lead to overmotivation, which is known to
hamper effective goal striving and undermine rates of goal attainment (Baumeister, 1984;
Heckhausen & Strang, 1988). Consistent with this idea, none of the BCTs that concerned
improving motivation (i.e., BM codes in Michie, Hyder, et al.’s 2011 taxonomy) proved
effective. It has previously been reported that smokers with COPD may fall into two
motivational categories, namely those who are unmotivated to quit and would benefit
from motivational techniques, and participants who are motivated to quit and would
benefit from volitional interventions such as implementation intentions (Hilberink,
Jacobs, Schlosser, Grol, & de Vries, 2006). It may be important, therefore, to tailor
interventions appropriately. This review suggests that, for smokers with COPD who
participated in these interventions, building self-regulation capacity and skills that
facilitate the translation ofmotivation into actionmay bemore important than techniques
aimed at merely increasing motivation to quit smoking. The implication is that future
studies would do well to measure motivation and self-regulation capacity prior to
conducting the intervention, so that time and resources can be devoted to the particular
issues faced by participants (forming strong intentions to quit and/or the effective
implementation of quit intentions).
Limitations and directions for future research
The main limitation of the present review is the paucity of RCTs that were available for
analysis (k = 17). The quality of the included studies was variable, with 7 of 17 falling
below the threshold for ‘high quality’ (van der Meer et al., 2003). Furthermore, only 10
studies reported an a priori power calculation, and only 9 studies were adequately
powered according to Coyne et al.’s (2010) criteria. Although both the funnel plot and
Egger’s regression suggest that publication bias does not present a problem for this
review, including unpublished or grey literaturemayhave allowed a larger sample of RCTs
to be considered. In future, the inclusion of high-quality grey literature should be
considered.
Descriptions of the BCTs used in interventions in the original articles were often brief,
and while efforts were made to retrieve further information, the full range of BCTs
deployed may not have been captured in all studies. It has been reported recently that
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fewer than one-half of the BCTs listed in intervention manuals and protocols are reported
in the final publications (Lorencatto, West, Stavri, & Michie, 2012). The introduction of
online supplements and requiring submission of the full intervention protocol before
publication of RCTs should mean that reports of protocols will improve in future,
although Lorencatto, West, Stavri, et al. (2012) have not found evidence of this
improvement thus far. A related difficulty is that there is noway of knowingwhether all of
the reported BCTs were actually delivered during the intervention. Finally, the large
number of moderators considered introduces the potential of some being significant by
chance. To address this issue, the higher-level categorieswithin theMichie, Hyder, et al.’s
(2011) taxonomy (motivation, self-regulatory capacity/skills, adjuvant activities, and
general aspects of the interaction) were also considered. This approach was taken in a
previous review identifying effective approaches to increase exercise-related self-efficacy
(Ashford, Edmunds, & French, 2010). However, although the majority of interventions in
the present review included techniques from all four categories, only two categories
reached the necessary k ≥ 3 tests in both the absence and presence categories. These
limitations are inherent to coding BCTs froma small number of published reports. Analysis
with a greater number of primary studies, specifically investigating the roles ofmotivating
and self-regulating BCTs for people with COPD, and how these techniques are being
delivered would consolidate these initial results and allow for more confidence in
designing smoking cessation interventions for this population. Additional RCTs of
smoking cessation interventions for people with COPD should be a priority in future
research (Parker & Eaton, 2012).
Additional studies are needed to permit more powerful tests of the effectiveness of
BCTs and more authoritative analyses of the specific BCTs that engender the greatest
cessation rates. As current UK practice is to refer people with COPD to the SSS, any new
interventions should be evaluated in relation to the quit rates observed in the SSS. Future
studies also need to be adequately powered and whenever possible should adopt the
‘Russell Standard’ for the measurement of smoking cessation (6- or 12-month
biochemically validated abstinence; West, Hajek, Stead, & Stapleton, 2005). Finally,
reports of RCTs should follow the CONSORT recommendation (Schulz, Altman, &
Moher, 2010) that all intervention procedures are described ‘with sufficient details to
allow replication’ (p. 699) to facilitate cumulative knowledge concerning the effective-
ness of BCTs.
Conclusions
This meta-analysis aimed to identify the most effective BCTs used in smoking cessation
interventions for people with COPD. Seventeen RCTs were identified, a mean quit rate of
13.19% and a sample-weighted average effect size of 0.33were observed. Two BCTswere
contraindicated, and five BCTswere associatedwith improved effectiveness. The present
findings suggest that boosting motivation and assessing nicotine dependence may be
counterproductive, whereas facilitating action planning, prompting self-recording,
offering advice on weight control and the use of support, and linking COPD and smoking
should each prove helpful in future smoking cessation interventions for people with
COPD. Further research, including studies investigating interventions tailored according
to an individual’s initial motivation and self-regulatory capacity, is needed to corroborate
the findings obtained here. More and better-quality studies will help to identify the most
effective BCTs and so ensure that smoking cessation interventions for people with COPD
are as effective as possible.
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Supporting Information
The following supporting informationmay be found in the online edition of the article:
Table S1. Functional classification of the smoking cessation taxonomy, as described in
the supplementary material for Michie, Churchill et al. (2011).
Table S2. Intervention characteristics.
Table S3. Sample characteristics.
Figure S1. Funnel plot.
Appendix 1: Full search strategy
1. Lung disease*, obstructive (mapped to subject heading where applicable).
2. Pulmonary disease, chronic obstructive (mapped to subject heading, exploded if
applicable).
3. Emphysema*.
4. (chronic adj3/N3 bronchitis*).
5. (obstruct* adj3/N3 (lung* or airway* or airflow* or bronch* or respirat*)).
6. COPD or COAD or COBD or AECB.
7. 1 or 2 or 3 or 4 or 5 or 6.
8. Exercise or ‘exercise movement therapy’ or ‘exercise therapy’ or kinisio*therapy.
9. (physical or exercise)adj/N1 (train* or fitness or activit* or therap*).
10. 8 or 9.
11. Abstain* or smok* or giv* or tobacco* or nicotine* or anti*smoking or quit* or stop* or
cessat* or ceas* or abstin*.
12. Pursed lip breath* or diaphragm* breath or breath* or inspiri* or ‘ventilation
feedback training’ or yoga or ‘chest physiotherapy’ or ‘chest physical therapy’.
13. Behav* or intervention*.
14. 10 or 11 or 12.
15. 7 and 14 and 13.
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